Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.03.047PMID 16157940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients

  2004cited by this paper
• Human papillomavirus vaccines and prevention of cervical cancer.

  2004cited by this paper
• Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.

  2003cited by this paper
• Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others.

  2003cited by this paper
• A controlled trial of a human papillomavirus type 16 vaccine. Koutsky LA, Ault KA, Wheeler CM, et al. N Engl J Med 2002; 347: 1645-1651

  2003cited by this paper
• T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

  2002cited by this paper
• A controlled trial of a human papillomavirus type 16 vaccine.

  2002cited by this paper
• Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.

  2002cited by this paper
• Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.

  2002cited by this paper
• Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

  2002cited by this paper
• Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

  2002cited by this paper
• Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

  2002cited by this paper
• Tumor Vaccines

  2002cited by this paper
• Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.

  2001cited by this paper
• Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

  2000cited by this paper
• Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.

  2000cited by this paper
• Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.

  1999cited by this paper
• Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

  1999cited by this paper
• Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

  1999cited by this paper
• Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.

  1998cited by this paper
• Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer

  1998cited by this paper
• Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

  1998cited by this paper
• Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

  1997cited by this paper
• Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.

  1997cited by this paper
• Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

  1996cited by this paper
• Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

  1996cited by this paper
• Association of gastric adenocarcinoma with the HLA class II gene DQB10301.

  1996cited by this paper
• Factors associated with melanoma incidence and prognosis.

  1996cited by this paper
• Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

  1995cited by this paper
• Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

  1995cited by this paper
• In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.

  1994cited by this paper
• HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.

  1994cited by this paper
• Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.

  1993cited by this paper
• Distribution of HLA Antigens

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Tuberculin reaction size measurement by the pen method compared to traditional palpation.

  1987cited by this paper
• Measurement of Delayed Skin-Test Responses

  1975cited by this paper
• Editorial: Measurement of delayed skin-test responses.

  1975cited by this paper

• Cell membrane vaccine delivery system: A review of the recent advances against breast cancer.

  2025cites this paper
• Breast cancer vaccines: from immune promise to the prospect of eradication

  2025cites this paper
• Recent advances in immunotherapy for breast cancer

  2025cites this paper
• AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients

  2024cites this paper
• Therapeutic Vaccination Strategies for Breast Cancer

  2024cites this paper
• FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

  2024cites this paper
• Vaccines for breast cancer prevention: Are we there yet?

  2024cites this paper
• Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

  2023cites this paper
• Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells

  2023cites this paper
• Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.

  2023cites this paper
• Cytokine-induced killer cell treatment is superior to chemotherapy alone in esophageal cancer

  2023cites this paper
• Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence

  2023cites this paper
• Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape

  2023cites this paper
• Breast cancer vaccination: Latest advances with an analytical focus on clinical trials.

  2023cites this paper
• Recent Progress on Therapeutic Vaccines for Breast Cancer

  2022cites this paper
• Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic Targets as a New Approach for Breast Cancer: A Review

  2022cites this paper
• The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines

  2022cites this paper
• Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions

  2022cites this paper
• Vakzinierungsstrategien beim Mammakarzinom

  2022cites this paper
• Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model

  2022cites this paper
• Immunological Landscape of HER-2 Positive Breast Cancer

  2022cites this paper
• Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine

  2022cites this paper
• Breast Cancer Vaccines: Disappointing or Promising?

  2022cites this paper
• Immuno-oncology in triple-negative breast cancer

  2021cites this paper
• Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making

  2021cites this paper
• Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

  2021influential citation
• Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.

  2021cites this paper
• Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice

  2021cites this paper
• Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options.

  2021cites this paper
• Tumorvakzinierung –Strategien und Timing

  2021cites this paper
• Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis

  2021cites this paper
• Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence

  2021cites this paper
• Tumor Microenvironment

  2020cites this paper
• Immunopathology and Immunotherapy for Breast Cancer

  2020cites this paper
• Immuntherapie beim Mammakarzinom

  2020cites this paper
• BCTT_A_224758 69..75

  2020cites this paper
• Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond

  2020cites this paper
• The Immune Landscape in Women Cancers.

  2020cites this paper
• Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

  2020cites this paper
• Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies

  2020cites this paper
• Immunonkologie beim triple-negativen Mammakarzinom

  2019cites this paper
• Candidate Cancers for Vaccination

  2019cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• What therapies are on the horizon for HER2 positive breast cancer?

  2019cites this paper
• Immunotherapy in breast cancer: Current status and future directions.

  2019cites this paper
• Peptide vaccines in early breast cancer.

  2019cites this paper
• Targeted therapeutic options and future perspectives for HER2-positive breast cancer

  2019cites this paper
• Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

  2019cites this paper
• Vaccine Therapies for Breast Cancer.

  2019cites this paper
• Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

  2019cites this paper
• Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

  2019cites this paper
• Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial

  2019influential citation
• The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies.

  2019cites this paper
• Developing peptide vaccines for breast cancer

  2018cites this paper
• Immunological Cellular Therapies and Gene Therapies

  2018cites this paper
• Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta‐analysis

  2018cites this paper
• Rational combinations of in vivo cancer antigen priming and adoptive T-cell therapy mobilize immune and clinical responses in terminal cancers

  2018cites this paper
• Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy

  2018cites this paper
• Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer

  2018cites this paper
• In silico analysis of chimeric subunit vaccine containing HER-2-MUC1 against breast cancer

  2018cites this paper
• HER2-Based Immunotherapy for Breast Cancer

  2018cites this paper
• Immune Regulation in Breast Cancer Metastasis and Immunotherapy

  2017cites this paper
• Mécanismes de l’immunogénicité des cellules cancéreuses hyperploïdes

  2017cites this paper
• Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial

  2017cites this paper
• Anti-tumor activity of dendritic cell-cytokine induced killer cells ( DC-CIKs ) sensitized to HER 2 against HER-positive breast cancer cells

  2017cites this paper
• Novel treatment strategies in cancer immunotherapy

  2017cites this paper
• 6.01 – Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R

  2017cites this paper
• Breast Cancer Vaccines: New Insights

  2017cites this paper
• The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives.

  2017cites this paper
• A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice

  2016cites this paper
• Immunotherapy of Cancer (Review)

  2016cites this paper
• Anti-tumor activity of dendritic cell-cytokine induced killer cells (DC-CIKs) sensitized to HER2 against HER-positive breast cancer cells.

  2016cites this paper
• Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial

  2016cites this paper
• A therapeutic Her 2 / neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her 2 / neu-expressing tumor in HLA-A 2 transgenic mice

  2016cites this paper
• Anti-tumor activity of dendritic cell-cytokine induced killer cells ( DC-CIKs ) sensitized to HER 2 against HER-positive breast cancer cells

  2016cites this paper
• Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

  2016cites this paper
• Injecting Hope--A Review of Breast Cancer Vaccines.

  2016cites this paper
• Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients

  2016cites this paper
• Peptide-Based Cancer Vaccine Strategies and Clinical Results.

  2016cites this paper
• Emerging Therapeutic Options for HER2-Positive Breast Cancer.

  2016cites this paper
• Immunotherapy in Breast Cancer- Paving New Roads?

  2016cites this paper
• Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis.

  2016cites this paper
• Development of MHC class II-restricted TCR gene therapy for Epstein Barr virus associated malignancies

  2016cites this paper
• Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

  2016cites this paper
• A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

  2016cites this paper
• The development and use of the E75 (HER2 369-377) peptide vaccine.

  2016cites this paper
• Anti-tumor activity of dendritic cell-cytokine induced killer cells (DC-CIKs) sensitized to HER2 against HER-positive breast cancer cells.

  2016cites this paper
• Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer

  2016cites this paper
• Clinical Development of the E75 Vaccine in Breast Cancer

  2016cites this paper
• Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

  2015cites this paper
• Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma

  2015cites this paper
• Defining and managing expectations for early immunotherapy cancer trials.

  2015cites this paper
• Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.

  2015cites this paper
• HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy

  2015cites this paper
• Trial Watch: Peptide-based anticancer vaccines

  2015cites this paper
• Breast Cancer Immunotherapy.

  2015cites this paper
• Peptide vaccines in breast cancer: The immunological basis for clinical response.

  2015cites this paper
• Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches

  2015cites this paper
• Adjuvant HER2/neu peptide cancer vaccines in breast cancer.

  2015cites this paper
• Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer

  2014cites this paper